Press release
Osteoarthritis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pha
Osteoarthritis Pipeline Analysis
DelveInsight reports that over 100 key companies are actively involved in the development of more than 110 therapeutic candidates for the treatment of osteoarthritis.
Osteoarthritis Overview:
Osteoarthritis (OA) is the most common type of arthritis and is often called degenerative joint disease or "wear and tear" arthritis. It mainly affects the knees, hips, and hands, progressing gradually as joint cartilage breaks down and underlying bone undergoes structural changes. Over time, these changes can lead to pain, stiffness, swelling, and, in more severe cases, reduced mobility and disability, making daily activities and work more difficult.
Typical symptoms include joint pain that worsens with activity and improves with rest, stiffness lasting less than 30 minutes after periods of inactivity, and a feeling of joint instability. Affected joints may also produce grinding or creaking sounds during movement, and swelling may occur, especially after prolonged use.
Request for a detailed insights report on Osteoarthritis pipeline insights [https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Osteoarthritis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Osteoarthritis Therapeutics Market.
Key Takeaways from the Osteoarthritis Pipeline Report
*
DelveInsight's Osteoarthritis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Osteoarthritis treatment.
*
In December 2024, Bioventus entered into a nationwide contract with Aetna Medicare Advantage plans, granting over 3 million members access to DUROLANE for knee osteoarthritis pain treatment, effective January 1, 2024.
*
Levicept announced in December 2024 that it had completed recruitment for its Phase II clinical trial of LEVI-04, an innovative neurotrophin-modulating biological agent, with top-line results expected in the late first half of 2024.
*
BioSolution plans to seek conditional product approval for CARTILIFE from the US FDA in 2024. The company is currently conducting Phase II clinical trials in the US, with the last patient set to receive treatment. Final results could be available by the end of 2024.
*
Key Osteoarthritis companies such as Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics, and others are evaluating new drugs for Osteoarthritis to improve the treatment landscape.
*
Promising Osteoarthritis pipeline therapies in various stages of development include Lorecivivint, EP-104IAR, DFV890, 4P004, GNSC 001, and others.
Osteoarthritis Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Osteoarthritis Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoarthritis treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Osteoarthritis market.
Download our free sample page report on Osteoarthritis pipeline insights [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Osteoarthritis Emerging Drugs
*
Lorecivivint: Biosplice Therapeutics
*
EP-104IAR: Eupraxia Pharmaceuticals
*
DFV890: Novartis
*
4P004: 4P-Pharma
*
GNSC 001: Genascence
Osteoarthritis Companies
Over 100 prominent companies are currently engaged in developing treatments for osteoarthritis. Among them, Biosplice Therapeutics has drug candidates that have reached the most advanced stage-Phase III clinical trials.
DelveInsight's report covers around 80+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Osteoarthritis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Osteoarthritis Therapies and Key Companies: Osteoarthritis Clinical Trials and advancements [https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Osteoarthritis Pipeline Therapeutic Assessment
- Osteoarthritis Assessment by Product Type
- Osteoarthritis By Stage
- Osteoarthritis Assessment by Route of Administration
- Osteoarthritis Assessment by Molecule Type
Download Osteoarthritis Sample report to know in detail about the Osteoarthritis treatment market @ Osteoarthritis Therapeutic Assessment [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Osteoarthritis Current Treatment Patterns
4. Osteoarthritis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Osteoarthritis Late-Stage Products (Phase-III)
7. Osteoarthritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Osteoarthritis Discontinued Products
13. Osteoarthritis Product Profiles
14. Osteoarthritis Key Companies
15. Osteoarthritis Key Products
16. Dormant and Discontinued Products
17. Osteoarthritis Unmet Needs
18. Osteoarthritis Future Perspectives
19. Osteoarthritis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Osteoarthritis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteoarthritis-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-biosplice-therapeutics-cynata-therapeutics-bone-therapeutics-sa-regeneron-pha]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Osteoarthritis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pha here
News-ID: 4123664 • Views: …
More Releases from ABNewswire
Adapts.ai Redefines Software Maintenance and Modernization with GenAI-Powered Pl …
October 10, 2025 - In an era where digital transformation defines competitive advantage, Adapts.ai is emerging as a game-changer in enterprise application modernization and AI-driven digital transformation services. The platform leverages next-generation GenAI technology to simplify software maintenance, accelerate legacy code modernization, and empower engineering teams with intelligent automation.
Adapts addresses one of the most pressing challenges in modern software engineering - navigating outdated, poorly documented, and complex legacy codebases. Traditional…
A Journey Across Oceans and Generations: "From Germany With Love" Uncovers One F …
Julie Anne Brion never set out to write a history book. What she did want was to understand where she came from, and maybe, just maybe, help others feel a little less lost in their own search for belonging. The result is her newest book, From Germany With Love: Mit Liebe aus Deutschland , a deeply personal look at one family's journey from the heart of Europe to the promise…
New Book from Immigration Attorney Shares Practical Guidance for Securing a U.S. …
New York, NY - Immigrants working toward permanent residency in the United States now have a new guide to help them through the process. Anne Zeitoun-Sedki, an immigration attorney with more than 15 years of hands-on experience, whose YouTube channel has attracted millions of views worldwide, has published a book that simplifies the path to a U.S. green card.
The book draws on Zeitoun-Sedki's years of representing individuals and families from…
Kinghelm Antennas Power OBD Applications in Smart and New Energy Vehicles
Kinghelm, a leading RF and microwave technology company, provides high-performance antennas and connectors for OBD systems in smart and new energy vehicles. Together with partners Slkor Semiconductor and Avant Electronics, Kinghelm delivers integrated solutions for GPS/BDS positioning, Bluetooth/Wi-Fi transmission, and intelligent vehicle connectivity.
Image: https://www.abnewswire.com/upload/2025/10/0790f023c90e731790a4ec80533af9ea.jpg
Automotive OBD Products and Application Scenarios
As intelligent connected vehicles become increasingly mainstream, On-Board Diagnostics (OBD) systems have emerged as a vital component for ensuring driving safety, emissions…
More Releases for Osteoarthritis
Osteoarthritis Market Massive Growth opportunity Ahead
Introduction
Osteoarthritis (OA), the most common form of arthritis, remains a significant global health burden, causing pain, mobility limitations, and reduced quality of life for millions. Driven by an aging population, lifestyle-related factors like obesity, and a growing focus on musculoskeletal health, the osteoarthritis market is witnessing notable transformation.
According to Exactitude Consultancy, the global osteoarthritis market was valued at USD 14 billion in 2024 and is projected to reach USD 22…
Rising Sports Injuries Fuel Growth In Osteoarthritis Therapeutics Market: The Dr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Osteoarthritis Therapeutics Market Size Growth Forecast: What to Expect by 2025?
In recent times, the osteoarthritis therapeutics market has seen substantial growth. The market size was $8.17 billion in 2024 and is projected to rise to $8.87 billion in 2025, reflecting an annual compound growth rate (CAGR) of 8.6%.…
Osteoarthritis Treatment Market Trends and Forecast 2034
On March 20, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Osteoarthritis Treatment Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across…
Osteoarthritis Treatment Market
Introduction
Osteoarthritis (OA) is the most common form of arthritis, affecting millions worldwide. It is a degenerative joint disease that primarily impacts the cartilage and causes pain, stiffness, and reduced mobility. The growing prevalence of osteoarthritis, especially among the aging population, has created a significant demand for treatment options. The osteoarthritis treatment market includes various therapeutic approaches, such as medications, physical therapies, and surgical procedures, designed to manage the symptoms and…
Osteoarthritis Therapeutics Market - Finding Freedom from Osteoarthritis: Discov …
Newark, New Castle, USA: The "Osteoarthritis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Osteoarthritis Therapeutics Market: https://www.growthplusreports.com/report/osteoarthritis-therapeutics-market/7779
This latest report researches the industry structure, sales, revenue,…
Osteoarthritis Therapeutics Market: Rising Obese and Geriatric Populations to In …
Industry is experiencing significant growth due to the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment is likely to hamper the growth of the market.
What the Osteoarthritis Therapeutics Market Looks Like?
The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8…
